BioLineRx(BLRX) - 2022 Q4 - Annual Report
BioLineRx(BLRX)2023-03-21 16:00
Risks Related to our Operations in Israel Due to a significant portion of our expenses and revenues being denominated in non-dollar currencies, our results of operations may be harmed by currency fluctuations. 32 ARDS secondary to COVID-19 and other viral infections 38 Establishment of Scientific Advisory Board 39 Therapeutic Candidates Solid tumors. Novel, emerging therapeutic approaches for targeting solid tumors are being developed and tested. Combinational therapies of immune checkpoint inhibitors with ...